摘要
目的研究Caspase-3和Caspase-8在妊娠期高血压疾病胎盘组织中的表达及临床意义。方法随机选择2018年1~12月就诊于浙江省湖州市妇幼保健院的产妇共90例,分为正常妊娠组、妊娠期高血压组、子痫前期组,每组30例。收集所有产妇分娩胎盘组织,采用荧光实时定量RT-PCR和免疫组化方法,分别检测Caspase-3和Caspase-8基因和蛋白质表达水平及临床意义。结果Caspase-3和Caspase-8 mRNA在妊娠期高血压组、子痫前期组的表达水平均高于正常妊娠组,差异具有统计学意义(P<0.05);Caspase-3和Caspase-8蛋白质在正常妊娠组、妊娠期高血压组、子痫前期组胎盘组织的阳性率分别为23.33%与20%、56.67%与50.00%、76.67%与66.67%,疾病组妊娠期高血压组和子痫前期组与正常妊娠组比较差异具有统计学意义(P<0.05)。结论Caspase-3和Caspase-8 mRNA和蛋白质在妊娠期高血压疾病患者胎盘组织中的表达均呈强阳性,表达水平与妊娠期高血压疾病的发生、发展有相关性。
Objective To study the expression and clinical significance of Caspase-3 and Caspase-8 in the placenta of patients with hypertensive disorders of pregnancy.Methods A total of 90 pregnant women who visited Huzhou Maternal and Child Health Care Hospital from January 2018 to December 2018 were randomly selected.They were divided into three groups:normal pregnancy group,gestational hypertension group and preeclampsia group,with 30 cases in each group.The placentas of all the parturients were collected,and the mRNA and protein expression levels of Caspase-3 and Caspase-8were detected by real-time quantitative RT-PCR and immunohistochemistry,respectively,and their correlation with clinical manifestations was further analyzed.Results The expression levels of Caspase-3 and Caspase-8 mRNA in the gestational hypertension group and preeclampsia group were significantly higher than those in the normal pregnancy group(P0.05).The expression levels of Caspase-3 and Caspase-8 protein in the normal pregnancy group,gestational hypertension group and preeclampsia group were 23.33%/20%、56.67%/50.00%、76.67%/66.67%,respectively.The difference between the disease group and the normal group was statistically significant(P0.05).Conclusion The expression of Caspase-3 and Caspase-8m RNA and protein is correlated with the occurrence and development of gestational hypertension.
作者
高金来
梅丽娜
宁启鹏
楼朝霞
王丽
王涛
张姣
GAO Jinlai;MEI Lina;NING Qipeng;LOU Zhaoxia;WANG Li;WANG Tao;ZHANG Jiao(Huzhou Maternal and Child Health Care Hospital,Huzhou 313000,China)
出处
《浙江实用医学》
2023年第1期21-25,共5页
Zhejiang Practical Medicine
基金
浙江省医药卫生科技计划项目(2022KY1226)
湖州市公益性应用研究项目(2021GYB12)。